trending Market Intelligence /marketintelligence/en/news-insights/trending/R9Cs683MSQlNE_8R36F25w2 content esgSubNav
In This List

Aspen Pharmacare under investigation by UK competition watchdog

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Aspen Pharmacare under investigation by UK competition watchdog

The U.K. Competition and Markets Authority is investigating Aspen Pharmacare Holdings Ltd. for alleged anticompetitive conduct relating to the supply of blood pressure drug Fludrocortisone acetate and arthritis drug Dexamethasone, Reuters reported Oct. 13.

Aspen said in a statement that the investigation is at an early stage and the regulator has not yet reached a decision on whether competition law has been infringed, the news outlet reported.

The drugs under investigation had a combined revenue of £11.1 million in Britain in 2016.

Earlier in October, the Competition Commission of South Africa dropped its investigations into Aspen for suspected excessive pricing of certain cancer drugs. The investigation found that revenues for cancer drugs Myleran, Alkeran and Leukeran are very low as they were at the end of their lifespans.